vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -18.0%, a 19.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -76.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -4.6%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
PCRX vs WH — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $334.0M |
| Net Profit | $2.9M | $-60.0M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | -18.0% |
| Revenue YoY | 5.0% | -76.3% |
| Net Profit YoY | — | -170.6% |
| EPS (diluted) | $0.07 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $334.0M | ||
| Q4 25 | $196.9M | $334.0M | ||
| Q3 25 | $179.5M | $382.0M | ||
| Q2 25 | $181.1M | $397.0M | ||
| Q1 25 | $168.9M | $316.0M | ||
| Q4 24 | $187.3M | $336.0M | ||
| Q3 24 | $168.6M | $396.0M | ||
| Q2 24 | $178.0M | $367.0M |
| Q1 26 | $2.9M | $-60.0M | ||
| Q4 25 | — | $-60.0M | ||
| Q3 25 | $5.4M | $105.0M | ||
| Q2 25 | $-4.8M | $87.0M | ||
| Q1 25 | $4.8M | $61.0M | ||
| Q4 24 | — | $85.0M | ||
| Q3 24 | $-143.5M | $102.0M | ||
| Q2 24 | $18.9M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -11.4% | ||
| Q3 25 | 3.5% | 46.6% | ||
| Q2 25 | 4.7% | 37.8% | ||
| Q1 25 | 1.2% | 35.4% | ||
| Q4 24 | 13.2% | 38.4% | ||
| Q3 24 | -82.8% | 43.2% | ||
| Q2 24 | 15.9% | 39.5% |
| Q1 26 | 1.6% | -18.0% | ||
| Q4 25 | — | -18.0% | ||
| Q3 25 | 3.0% | 27.5% | ||
| Q2 25 | -2.7% | 21.9% | ||
| Q1 25 | 2.8% | 19.3% | ||
| Q4 24 | — | 25.3% | ||
| Q3 24 | -85.1% | 25.8% | ||
| Q2 24 | 10.6% | 23.4% |
| Q1 26 | $0.07 | $-0.80 | ||
| Q4 25 | $0.05 | $-0.77 | ||
| Q3 25 | $0.12 | $1.36 | ||
| Q2 25 | $-0.11 | $1.13 | ||
| Q1 25 | $0.10 | $0.78 | ||
| Q4 24 | $0.38 | $1.06 | ||
| Q3 24 | $-3.11 | $1.29 | ||
| Q2 24 | $0.39 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $64.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $468.0M |
| Total Assets | $1.2B | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $64.0M | ||
| Q4 25 | $238.4M | $64.0M | ||
| Q3 25 | $246.3M | $70.0M | ||
| Q2 25 | $445.9M | $50.0M | ||
| Q1 25 | $493.6M | $48.0M | ||
| Q4 24 | $484.6M | $103.0M | ||
| Q3 24 | $453.8M | $72.0M | ||
| Q2 24 | $404.2M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $2.5B | ||
| Q3 25 | $376.7M | $2.6B | ||
| Q2 25 | $580.5M | $2.5B | ||
| Q1 25 | $583.4M | $2.5B | ||
| Q4 24 | $585.3M | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | $653.9M | $468.0M | ||
| Q4 25 | $693.1M | $468.0M | ||
| Q3 25 | $727.2M | $583.0M | ||
| Q2 25 | $757.8M | $570.0M | ||
| Q1 25 | $798.5M | $579.0M | ||
| Q4 24 | $778.3M | $650.0M | ||
| Q3 24 | $749.6M | $583.0M | ||
| Q2 24 | $879.3M | $623.0M |
| Q1 26 | $1.2B | $4.2B | ||
| Q4 25 | $1.3B | $4.2B | ||
| Q3 25 | $1.3B | $4.3B | ||
| Q2 25 | $1.5B | $4.3B | ||
| Q1 25 | $1.6B | $4.2B | ||
| Q4 24 | $1.6B | $4.2B | ||
| Q3 24 | $1.5B | $4.2B | ||
| Q2 24 | $1.6B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 5.37× | ||
| Q3 25 | 0.52× | 4.43× | ||
| Q2 25 | 0.77× | 4.44× | ||
| Q1 25 | 0.73× | 4.29× | ||
| Q4 24 | 0.75× | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $367.0M |
| Free Cash FlowOCF − Capex | — | $168.0M |
| FCF MarginFCF / Revenue | — | 50.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $43.7M | $152.0M | ||
| Q3 25 | $60.8M | $86.0M | ||
| Q2 25 | $12.0M | $70.0M | ||
| Q1 25 | $35.5M | $59.0M | ||
| Q4 24 | $33.1M | $134.0M | ||
| Q3 24 | $53.9M | $79.0M | ||
| Q2 24 | $53.2M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $43.5M | $136.0M | ||
| Q3 25 | $57.0M | $75.0M | ||
| Q2 25 | $9.3M | $58.0M | ||
| Q1 25 | $26.9M | $52.0M | ||
| Q4 24 | $31.0M | $109.0M | ||
| Q3 24 | $49.8M | $71.0M | ||
| Q2 24 | $51.6M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 22.1% | 40.7% | ||
| Q3 25 | 31.7% | 19.6% | ||
| Q2 25 | 5.1% | 14.6% | ||
| Q1 25 | 15.9% | 16.5% | ||
| Q4 24 | 16.6% | 32.4% | ||
| Q3 24 | 29.6% | 17.9% | ||
| Q2 24 | 29.0% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.8% | ||
| Q3 25 | 2.2% | 2.9% | ||
| Q2 25 | 1.5% | 3.0% | ||
| Q1 25 | 5.1% | 2.2% | ||
| Q4 24 | 1.1% | 7.4% | ||
| Q3 24 | 2.4% | 2.0% | ||
| Q2 24 | 0.9% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | 7.37× | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | 2.82× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
